Patents Assigned to Enterprise Ireland
-
Patent number: 8946127Abstract: Use of the ssrA gene or tmRNA, an RNA transcript of the ssrA gene, or fragments thereof as target regions in a nucleic acid probe assay for the detection and identification of prokaryotic and/or eukaryotic organisms is described. Nucleotide sequence alignment of tmRNA sequences from various organisms can be used to identify regions of homology and non-homology within the sequences which in turn can be used to design both genus specific and species specific oligonucleotide probes. These newly identified regions of homology and non-homology provide the basis of identifying and detecting organisms at the molecular level. Oligonucleotide probes identified in this way can be used to detect tmRNA in samples thereby giving an indication of the viability of non-viral organisms present in various sample types.Type: GrantFiled: March 4, 2013Date of Patent: February 3, 2015Assignees: Enterprise Ireland, National University of IrelandInventors: Thomas Gerard Barry, Terence James Smith
-
Patent number: 7972777Abstract: Use of the ssrA gene or tmRNA, an RNA transcript of the ssrA gene, or fragments thereof as target regions in a nucleic acid probe assay for the detection and identification of prokaryotic and/or eukaryotic organisms is described. Nucleotide sequence alignment of tmRNA sequences from various organisms can be used to identify regions of homology and non-homology within the sequences which in turn can be used to design both genus specific and species specific oligonucleotide probes. These newly identified regions of homology and non-homology provide the basis of identifying and detecting organisms at the molecular level. Oligonucleotide probes identified in this way can be used to detect tmRNA in samples thereby giving an indication of the viability of non-viral organisms present in various sample types.Type: GrantFiled: May 15, 2000Date of Patent: July 5, 2011Assignees: Enterprise Ireland, National University of Ireland, GalwayInventors: Thomas Gerard Barry, Terence James Smith
-
Patent number: 7741461Abstract: The current invention relates to the field of detection and identification of clinically important fungi. More particularly, the present invention relates to species specific probes originating from the Internal Transcribed Spacer (ITS) region of rDNA for the detection of fungal species such as Candida albicans, Candida parapsilosis, Candida tropicalis, Candida kefyr, Candida krusei, Candida glabrata, Candida dubliniensis, Aspergillus flavus, Aspergillus versicolor, Aspergillus nidulans, Aspergillus fumigatus, Cryptococcus neoformans and Pneumocystis carinii in clinical samples, and methods using said probes.Type: GrantFiled: October 19, 2004Date of Patent: June 22, 2010Assignees: Innogenetics N.V., Enterprise Ireland, National University of Ireland GalwayInventors: Terry Smith, Majella Maher, Cara Martin, Geert Jannes, Rudi Rossau, Marjo Van der Weide
-
Patent number: 7195906Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatroy activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.Type: GrantFiled: February 23, 2004Date of Patent: March 27, 2007Assignees: Enterprise Ireland (Trading as BioResearch Ireland), University College Cork--National University of IrelandInventors: John Kevin Collins, Gerald Christopher O'Sullivan, Liam O'Mahony, Fergus Shanahan
-
Patent number: 7186545Abstract: A strain of Lactobacillus salivarius isolated from resected and washed human gastrointestinal tract inhibits a broad range of Gram positive and Gram negative microorganisms and secretes a product having antimicrobial activity into a cell-free supernatant. The activity is produced only by, growing cells and is destroyed by proteinase K and pronase E, the inhibitory properties of the strain and its secretory products being maintained in the presence of physiological concentrations of human bile and human gastric juice. The strain exhibits a broad-spectrum of activity against bacteria including Listeria, Staphylococcus, including methocillin resistant St. aureus (MRSA), and Bacillus, but does not inhibit many closely related lactobacilli. An antimicrobial agent is obtained from the strain which has bacteriocin-like properties.Type: GrantFiled: June 26, 2003Date of Patent: March 6, 2007Assignees: Enterprise Ireland, University College Cork - National University of IrelandInventors: John Kevin Collins, Gerald Christopher O'Sullivan, Gerardine Mary Thornton, Marian Mary Geraldine O'Sullivan
-
Patent number: 7175982Abstract: The present invention is drawn to a method for characterising nucleic acid molecules, which comprises the steps of: i) introducing a modified base which is a substrate for a DNA glycosylase into a DNA molecule; ii) excising the modified base with the DNA glycosylase to generate an abasic site; iii) cleaving the DNA at the abasic site to generate and release an extendible upstream DNA fragment having a 3? hydroxyl terminus; and iv) incubating the released extendible upstream DNA fragment in the presence of an enzyme allowing for extension thereof and an additional template nucleic acid and analysing resultant fragment(s).Type: GrantFiled: April 22, 1998Date of Patent: February 13, 2007Assignees: Enterprise Ireland (T/A BioResearch Ireland), University College Cork Natl. University of IrelandInventors: Thomas Valentine McCarthy, Patrick Martin Vaughan
-
Patent number: 6872411Abstract: A process for the manufacture of a probiotic cheese, such as Cheddar cheese, comprises adding a 0.0-5.5% inoculum of a strain of Lactobacillus paracasei, which is non-pathogenic, acid and bile tolerant and adherent to human epithelial cells, as a starter adjunct to cheese milk, said L. paracasei strain being capable of growing during the ripening phase to a level of 107 cfu/g or greater. The L. paracasei strains are found to grow and proliferate to high cell numbers (in excess of 108 cfu/g) in the cheese over eight months of ripening, even when added at a relatively low inoculum. The presence of the L. paracasei strains is found to have negligible effects on cheese composition, flavor and aroma.Type: GrantFiled: May 26, 1999Date of Patent: March 29, 2005Assignees: Enterprise Ireland, Teagasc, The Agriculture and Food Development AuthorityInventors: Reynolds Paul Ross, Gerald Francis Fitzgerald, John Kevin Collins, Gerald Christopher O'Sullivan, Catherine Gerardine Stanton
-
Patent number: 6858387Abstract: The current invention relates to the field of detection and identification of clinically important fungi. More particularely, the present invention relates to species specific probes originating from the Internal Transcribed Spacer (ITS) region of rDNA for the detection of fungal species such as Candida albicans, Candida parapsilosis, Candida tropicalis, Candida kefyr, Candida krusei, Candida glabrata, Candida dubliniensis, Aspergillus flavus, Aspergillus versicolor, Aspergillus nidulans, Aspergillus fumigatus, Cyptococcus neoformans and Pneumocystis carinii in clinical samples, and methods using said probes.Type: GrantFiled: September 15, 2000Date of Patent: February 22, 2005Assignees: Innogenetics, N.V., Enterprise IrelandInventors: Terry Smith, Majella Maher, Cara Martin, Geert Jannes, Rudi Rossau, Marjo Van Der Weide
-
Publication number: 20040214304Abstract: A strain of Lactobacillus salivarius isolated from resected and washed human gastrointestinal tract inhibits a broad range of Gram positive and Gram negative microorganisms and secretes a product having antimicrobial activity into a cell-free supernatant. The activity is produced only by, growing cells and is destroyed by proteinase K and pronase E, the inhibitory properties of the strain and its secretory products being maintained in the presence of physiological concentrations of human bile and human gastric juice. The strain exhibits a broad-spectrum of activity against bacteria including Listeria, Staphylococcus, including methocillin resistant St. aureus (MRSA), and Bacillus, but does not inhibit many closely related lactobacilli. An antirmicrobial agent is obtained from the strain which has bacteriocin-like properties.Type: ApplicationFiled: June 26, 2003Publication date: October 28, 2004Applicant: Enterprise Ireland and University College Cork-National University of Ireland, CorkInventors: John Kevin Collins, Gerald Christopher O'Sullivan, Gerardine Mary Thornton, Marian Mary Geraldine O'Sullivan
-
Publication number: 20040038379Abstract: A strain of Lactobacillus salivarius isolated from resected and washed human gastrointestinal tract inhibits a broad range of Gram positive and Gram negative microorganisms and secretes a product having antimicrobial activity into a cell-free supernatant. The activity is produced only by growing cells and is destroyed by proteinase K and pronase E, the inhibitory properties of the strain and its secretory products being maintained in the presence of physiological concentrations of human bile and human gastric juice. The strain exhibits a broad-spectrum of activity against bacteria including Listeria, Staphylococcus, including methocillin resistant St. aureus (MRSA), and Bacillus, but does not inhibit many closely related lactobacilli. An antimicrobial agent is obtained from the strain which has bacteriocin-like properties.Type: ApplicationFiled: June 26, 2003Publication date: February 26, 2004Applicants: Enterprise Ireland and University College Cork -, National University of Ireland, CorkInventors: John Kevin Collins, Gerald Christopher O'Sullivan, Gerardine Mary Thornton, Marian Mary Geraldine O'Sullivan
-
Publication number: 20030215467Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatroy activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.Type: ApplicationFiled: March 17, 2003Publication date: November 20, 2003Applicant: Enterprise Ireland (Trading as Bioresearch Ireland and National University of Ireland, Cork.Inventors: John Kevin Collins, Gerald Christopher O'Sullivan, Liam O'Mahony, Fergus Shanahan
-
Publication number: 20030170217Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatroy activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.Type: ApplicationFiled: March 3, 2003Publication date: September 11, 2003Applicant: Enterprise Ireland (Trading as Bioresearch Ireland and National University of Ireland, Cork.Inventors: John Kevin Collins, Gerald Christopher O'Sullivan, Liam O'Mahony, Fergus Shanahan
-
Publication number: 20030166257Abstract: Lactobacillus salivarius is useful in the prophylaxis or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer. The Lactobacillus salivarius is of human origin isolated from resected and washed human gastrointestinal tract. One such strain is UCC 118 described in WO-A-9835014.Type: ApplicationFiled: September 12, 2002Publication date: September 4, 2003Applicant: Enterprise IrelandInventors: John Kevin Collins, Gerald Christopher O'Sullivan, Liam O'Mahony, Fergus Shanahan
-
Publication number: 20030113809Abstract: An in vitro test for testing the immunomodulatory especially anti-inflammatory or pro-inflammatory effect of a test material comprises placing a microporous support having a monolayer of epithelial cells therein in contact with a nutrient medium in a culture well. Cells of the immune system such as peripheral blood mononuclear cells are introduced into the medium and a test material is also introduced into the nutrient medium. A change in an immunological marker, especially a cytokine, particularly TNF&agr; or IL-8 in response to the test material is determined. The test material may be a strain of Lactobacillus or Bifidobacterium or other material which may be a probiotic.Type: ApplicationFiled: June 18, 2002Publication date: June 19, 2003Applicant: Enterprise Ireland (trading as BioResearch Ireland) and National University of Ireland, Cork.Inventors: John Kevin Collins, Liam O'Mahony
-
Patent number: 6413937Abstract: A combination of an agent which is a substrate for multidrug resistance related protein (MRP) and an inhibitor of MRP which is a nonsteroidal anti-inflammatory drug (NSAID) or a structural analogue thereof for simultaneous, sequential or separate use for increasing the potency of the substrate. The substrates include anti-cancer drugs and transition metal complexes. The combinations can be used to overcome the resistance to MRP substrates exhibited in many conditions, such as resistance to chemotherapy where patients have developed resistance, especially as a result of MRP over-expression to their chemotherapy.Type: GrantFiled: April 29, 1999Date of Patent: July 2, 2002Assignee: Dublin City University and Enterprise IrelandInventor: Martin Michael Clynes